Where I see patients (4)
Selected research
-
Travel Time to Treating Center is Associated With Diagnostic Delay in Pediatric Inflammatory Bowel Disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
-
Toxigenic Clostridium perfringens Isolated from At-Risk Paediatric Inflammatory Bowel Disease Patients.
Journal of Crohn's & colitis
-
Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis.
Journal of pediatric gastroenterology and nutrition
Clinical trials
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulc...
Clinical Remission based on the MMS
Recruiting
More about this studyClinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
The achievement of complete healing (CH) 52 weeks after initiation of anti-TNF therapy guided by ROADMABâ„¢ (therapeutic drug monitoring) as evidenced by a composite of all of the following four features below: 1. Endoscopic heal...
Recruiting
More about this studyImproving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Throug...
The primary outcome is the change in patient activation from baseline, with a 4-point improvement on Patient Activation Measure (PAM) scale considered a minimal clinically important difference (MCID). Patient activation is an asse...
Recruiting
More about this studyA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Clinical response based on PCDAI, and endoscopic response based on SES-CD.
Recruiting
More about this studyA Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Act...
Recruiting
More about this studyContact me
Learning never stops